# Enanta Pharmaceuticals, Inc. (ENTA)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/ENTA/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 17.16M | $ -13.09M | $ 0 | $ 186.62M | $ 116.59M |
| 2025 | $ 68.58M | $ -73.25M | $ -18.91M | $ 193.18M | $ 126.59M |
| 2024 | $ 69.99M | $ -110.29M | $ -101.41M | $ 221.29M | $ 111.82M |
| 2023 | $ 79.60M | $ -149.47M | $ -107.25M | $ 220.00M | $ 191.88M |
| 2022 | $ 91.71M | $ -134.75M | $ -125.19M | $ 26.77M | $ 300.84M |
| 2021 | $ 110.52M | $ -119.80M | $ -82.38M | $ 20.93M | $ 384.38M |
| 2020 | $ 129.49M | $ -73.81M | $ -27.15M | $ 10.20M | $ 452.00M |
| 2019 | $ 242.51M | $ 43.65M | $ 61.96M | $ 10.75M | $ 482.29M |
| 2018 | $ 314.86M | $ 113.94M | $ 68.95M | $ 271.0K | $ 426.84M |
| 2017 | $ 175.81M | $ 46.32M | $ 69.86M | $ 358.0K | $ 317.58M |
| 2016 | $ 69.12M | $ -13.07M | $ 7.52M | $ 515.0K | $ 268.17M |
| 2015 | $ 185.09M | $ 88.70M | $ 151.64M | $ 582.0K | $ 264.28M |
| 2014 | $ 175.70M | $ 115.61M | $ 27.10M | $ 200.0K | $ 193.71M |
| 2013 | $ 7.23M | $ -25.17M | $ -6.94M | $ 0 | $ 105.58M |
| 2012 | $ 99.36M | $ 67.16M | $ 49.98M | $ 0 | $ 66.22M |
| 2011 | $ 1.09M | $ -10.50M | $ -10.32M | $ 0 | $ -131.96M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 1.60 |
| Liabilities / Eq | 1.70 |
| Current Ratio | 3.84 |

## Other views

- [Metrics](https://sponda.capital/en/ENTA.md)
- [Charts](https://sponda.capital/en/ENTA/charts.md)
- [Compare](https://sponda.capital/en/ENTA/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-27.